HC Wainwright Raises Septerna (NASDAQ:SEPN) Price Target to $40.00

Septerna (NASDAQ:SEPN) had its price objective hoisted by investment analysts at HC Wainwright from $35.00 to $40.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 42.15% from the stock’s previous close.

SEPN has been the topic of several other research reports. Raymond James Financial began coverage on Septerna in a report on Friday, December 19th. They set a “strong-buy” rating and a $38.00 target price on the stock. Truist Financial started coverage on Septerna in a research note on Monday, December 15th. They issued a “buy” rating and a $34.00 price objective on the stock. Wall Street Zen cut shares of Septerna from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 10th. Wells Fargo & Company upgraded shares of Septerna from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $18.00 to $28.00 in a research report on Friday, November 14th. Finally, JonesTrading assumed coverage on shares of Septerna in a report on Tuesday, December 23rd. They issued a “buy” rating and a $43.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $34.67.

Septerna Trading Down 3.0%

SEPN traded down $0.88 on Monday, reaching $28.14. The company had a trading volume of 356,636 shares, compared to its average volume of 307,304. The company has a market capitalization of $1.26 billion, a P/E ratio of -18.61 and a beta of 3.43. The company has a fifty day moving average of $26.95 and a 200-day moving average of $22.42. Septerna has a one year low of $4.66 and a one year high of $32.63.

Insider Buying and Selling

In other news, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total transaction of $115,880.00. Following the transaction, the chief operating officer owned 174,209 shares in the company, valued at $5,046,834.73. This represents a 2.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Septerna

Hedge funds have recently bought and sold shares of the business. Group One Trading LLC raised its holdings in Septerna by 111.8% during the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after buying an additional 8,955 shares in the last quarter. Global Retirement Partners LLC acquired a new position in Septerna during the fourth quarter valued at approximately $35,000. Russell Investments Group Ltd. bought a new position in shares of Septerna in the third quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Septerna in the fourth quarter worth $53,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Septerna during the 4th quarter worth $61,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.